|By Business Wire||
|January 3, 2013 03:30 PM EST||
Cegedim Relationship Management today announced that Ranbaxy Laboratories Inc. has fully deployed the company’s groundbreaking Life Sciences compliance solution suite, including the market leading AggregateSpend360™, to more efficiently, proactively and successfully respond to today’s compounding regulatory environment. Ranbaxy Laboratories Inc., a wholly owned subsidiary of Ranbaxy Laboratories Limited, India’s largest pharmaceutical company, is engaged in the sale and distribution of branded prescription products in the U.S. healthcare system.
AggregateSpend360 Enables Dramatically Increased Data Visibility and Features Tailored to Compliance Functionalities
To satisfy the Sunshine Provisions of the Patient Protection and Affordable Care Act (PPACA), leading Life Sciences companies are focusing on effectively managing their brands, and connecting with targets across both pharmacy and prescription channels.
AggregateSpend360 alleviates Ranbaxy’s resources and time spent meeting the PPACA’s state/federal aggregate spend and disclosure reporting requirements. The solution collects and centralizes all transfers of value to practitioners – rationalizing the data into one customer view for optimal visibility. The cloud-based solution generates reports specific to each federal/state regulation. Further, the solution features unparalleled configuration flexibility to suit Ranbaxy’s distinctive business model needs, fostering cost-effectiveness now and in the future. AggregateSpend360 fully automates the compliance burden.
Customer Licensure and System Validation Provide Valuable Certainty of Database Quality and Network Effectiveness
Ranbaxy’s compliance solution suite also includes Cegedim’s Compliance ID Powered by OneKey™, which empowers companies to satisfy aggregate spend and disclosure reporting regulations through verified medical licensure information sourced from OneKey’s database of 12 million registered HCPs and one million healthcare organizations. Ranbaxy is also leveraging Cegedim’s BuzzeoPDMA compliance knowledge through Computer Systems Validation Services, which confirm that systems satisfy both state and federal regulatory standards.
“By aligning with Cegedim’s AggregateSpend360 and their compliance suite, we are staying well ahead of the curve regarding new U.S. legislation. Teams across the U.S enterprise – Primary Care, KOLs, Home Office, IT and Compliance teams – are now empowered with the tools to better track spending, improve data, and ensure that our technology is fully compliant,” said Dr. Ashish Anvekar, Senior Director of Ranbaxy Laboratories Inc. “Our company can achieve greater focus in providing patient-centric, quality and value-added pharmaceuticals.”
|About Cegedim Relationship Management:||
Cegedim Relationship Management is the Life Sciences industry’s
leading provider of Customer Relationship Management (CRM)
solutions. Designed specifically for Life Sciences, the company’s
innovative business solutions incorporate a thorough understanding
of local, regional and worldwide trends. Cegedim Relationship
Management enables more than 200,000 users in many of the world’s
most innovative companies to stay ahead of market challenges. In
addition to CRM, Cegedim Relationship Management also provides
marketing, data optimization and regulatory compliance solutions
in more than 80 countries. Cegedim Relationship Management is part
of the France-based Cegedim S.A. Group.
Founded in 1969, Cegedim is a global technology and services company specializing in the healthcare field. Cegedim supplies services, technological tools, specialized software, data flow management services and databases. Its offerings are targeted notably at healthcare industries, life sciences companies, healthcare professionals and insurance companies. The world leader in life sciences CRM, Cegedim is also one of the leading suppliers of strategic healthcare industry data. Cegedim employs 8,200 people in more than 80 countries and generated revenue of €911 million in 2011. Cegedim SA is listed in Paris (EURONEXT: CGM).